First Time in Man Study of Finafloxacin Hydrochloride
Completed
MerLion Pharmaceuticals GmbH
Phase 1
2007-08-01
The purpose of this study is to study the safety of single doses and multiple doses of
Finafloxacin hydrochloride in healthy volunteers. The level of Finafloxacin hydrochloride
will be measured in the subjects blood and urine. One part of the study will assess if
Finafloxacin hydrochloride eradicates Helicobacter pylori, a stomach bacteria. Another part
of the study will assess the activity of the drug in urine.
Efficacy and Safety Study of Finafloxacin Used in Helicobacter Pylori Infected Patients
Completed
MerLion Pharmaceuticals GmbH
Phase 2
2008-09-01
The primary objective of this study is to compare the H. pylori eradication rates with
Finafloxacin in combination with Amoxicillin or Esomeprazole.
The secondary objective is to evaluate and compare the safety and tolerability of multiple
oral doses of Finafloxacin plus Amoxicillin versus Finafloxacin plus Esomeprazole.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
